Company Overview and News

14
US private equity giants muscle in on Australia's home loan market

2018-10-18 theage.com.au
US private equity giants are muscling in on Australia's lucrative home loan business, shrugging off the risks of a falling market to seize an opportunity created by the retreat of the big local banks.
BGX PEP BGLF BX BGB

14
US private equity giants muscle in on Australia's home loan market

2018-10-18 watoday.com.au
US private equity giants are muscling in on Australia's lucrative home loan business, shrugging off the risks of a falling market to seize an opportunity created by the retreat of the big local banks.
BGX PEP BGLF BX BGB

14
US private equity giants muscle in on Australia's home loan market

2018-10-18 smh.com.au
US private equity giants are muscling in on Australia's lucrative home loan business, shrugging off the risks of a falling market to seize an opportunity created by the retreat of the big local banks.
BGX PEP BGLF BX BGB

2
UPDATE 2-KKR launches $1.2 bln buyout offer for Australia's MYOB Group

2018-10-08 reuters
SYDNEY (Reuters) - Australian accounting software provider MYOB Group (MYO.AX) said U.S. private equity firm KKR & Co (KKR.N) has launched a conditional A$1.75 billion ($1.24 billion) takeover offer for the company after buying a 19.9 percent stake.
INTU PEP MYO SGE

 
MYOB announces $1.75 bln buyout offer from KKR

2018-10-07 theage.com.au
Australia's MYOB Group on Monday said private equity firm KKR & Co proposed to buy shares it does not already own in the cloud services provider for about $1.75 billion after bagging a 17.6 per cent stake in MYOB from Bain Capital Abacus Holdings, L.P.
PEP MYO

 
MYOB announces $1.75 bln buyout offer from KKR

2018-10-07 watoday.com.au
Australia's MYOB Group on Monday said private equity firm KKR & Co proposed to buy shares it does not already own in the cloud services provider for about $1.75 billion after bagging a 17.6 per cent stake in MYOB from Bain Capital Abacus Holdings, L.P.
PEP MYO

 
MYOB announces $1.75 bln buyout offer from KKR

2018-10-07 smh.com.au
Australia's MYOB Group on Monday said private equity firm KKR & Co proposed to buy shares it does not already own in the cloud services provider for about $1.75 billion after bagging a 17.6 per cent stake in MYOB from Bain Capital Abacus Holdings, L.P.
PEP MYO

 
UPDATE 1-Australia's MYOB Group announces A$1.75 bln buyout offer from KKR

2018-10-07 reuters
Oct 8 (Reuters) - Australia’s MYOB Group on Monday said private equity firm KKR & Co proposed to buy shares it does not already own in the cloud services provider for about A$1.75 billion ($1.23 billion) after bagging a 17.6 percent stake in MYOB from Bain Capital Abacus Holdings, L.P.
PEP MYO

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:PEP / PEPPER GROUP LIMITED on message board site Silicon Investor.

PEP -- Time to buy? PEP -- Time to buy? PEP -- Time to buy? Pep Boys (PBY) Automotive Parts and Accessories Pep Boys (PBY) Automotive Parts and Accessories Pep Boys (PBY) Automotive Parts and Accessories
PETROSTAR PETROSTAR PETROSTAR Asia Pacific Enterprise APEP, starting today with PR Asia Pacific Enterprise APEP, starting today with PR Asia Pacific Enterprise APEP, starting today with PR
SgtPepperu0027s Picks from the Option Force Monitor SgtPepperu0027s Picks from the Option Force Monitor SgtPepperu0027s Picks from the Option Force Monitor Pepsi Bottling Company (PBG) Pepsi Bottling Company (PBG) Pepsi Bottling Company (PBG)
AAPL X CMB UNH PEP KO ZBRA Tim Lukeu0027s Position Tradig AAPL X CMB UNH PEP KO ZBRA Tim Lukeu0027s Position Tradig AAPL X CMB UNH PEP KO ZBRA Tim Lukeu0027s Position Tradig Peptech Limited (ASX: PTD) Peptech Limited (ASX: PTD) Peptech Limited (ASX: PTD)
PEP, pepsi sales force ideas. PEP, pepsi sales force ideas. PEP, pepsi sales force ideas. Earth Shakeru0027s Salt, Pepper and Most Precious Treasures Earth Shakeru0027s Salt, Pepper and Most Precious Treasures Earth Shakeru0027s Salt, Pepper and Most Precious Treasures